September 18th 2024
Your daily dose of the clinical news you may have missed.
September 17th 2024
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
September 13th 2024
Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.
Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.
September 12th 2024
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2
ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.
Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.
Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose
Nontraditional Risk Factors More Likely to Cause Stroke in Young Adults, Study Finds
Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.
FDA Approves Fixed-Dose Macitentan/Tadalafil Tablets for PAH: Daily Dose
Vaping Associated with Increased Risk of Heart Failure, According to New Research
ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.
Obesity Care Needs More Cardiology Support, Suggest 2 New Studies
ACC.2024: Two abstracts presented during the ACC Scientific Sessions indicate cardiologists are very hesitant to prescribe medical therapy for obesity.
Sustained LDL-C Control in High-Risk Group via Remote Lipid Program: Daily Dose
CAC Progression in Postmenopausal Women Found Double that of Men in New Research
ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.
Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy
ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.
Disparities in Coronary Artery Calcium Screening: Daily Dose
Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis
ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.
FDA Approves Aprocitentan for Treatment-Resistant HTN: Daily Dose
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
Sotagliflozin Impact on Stroke, MI to Be Explored in 4 Posters at ACC.24
The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
Remotely Delivered Lipid Lowering Program Results in Sustained Target LDL-C Levels in High-Risk Population
ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.
Concomitant SSRI and DOAC Use Increases Risk of Major Bleeding, Including ICH: New Findings
Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.
FDA Approves Fixed-Dose Macitentan/Tadalafil Tablets (Opsynvi) For Pulmonary Arterial Hypertension
For the first time, 2 drugs recommended as first line treatment for PAH are combined in a single oral once-daily therapy, which could reduced burden of care.
FDA Expands Bempedoic Acid Label to Include Primary, Secondary CV Risk Reduction, With or Without Statins
Bempedoic acid is now the only non-statin therapy indicated for primary CVD prevention, with potential to expand treatment access to millions, said Esperion Therapeutics.
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First
CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.